278 related articles for article (PubMed ID: 9491969)
1. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine.
Fraser AD; Howell P
J Anal Toxicol; 1998; 22(1):50-4. PubMed ID: 9491969
[TBL] [Abstract][Full Text] [Related]
2. False-positive immunoassay results for urine benzodiazepine in patients receiving oxaprozin (Daypro).
Camara PD; Audette L; Velletri K; Breitenbecher P; Rosner M; Griffiths WC
Clin Chem; 1995 Jan; 41(1):115-6. PubMed ID: 7813058
[No Abstract] [Full Text] [Related]
3. Development and validation of a high-performance liquid chromatography method for the evaluation of niflumic acid cross-reactivity of two commercial immunoassays for cannabinoids in urine.
Kovatsi L; Pouliopoulos A; Papadaki A; Samanidou V; Tsoukali H
J Anal Toxicol; 2010 May; 34(4):229-32. PubMed ID: 20465870
[TBL] [Abstract][Full Text] [Related]
4. Interference of oxaprozin with benzodiazepines via enzyme immunoassay technique.
Matuch-Hite T; Jones P; Moriarity J
J Anal Toxicol; 1995; 19(2):130. PubMed ID: 7769785
[No Abstract] [Full Text] [Related]
5. Improved cross-reactivity to alpha OH triazolam in the BMC CEDIA DAU urine benzodiazepine assay.
Fraser AD; Meatherall R
Ther Drug Monit; 1998 Jun; 20(3):331-4. PubMed ID: 9631932
[TBL] [Abstract][Full Text] [Related]
6. Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabinoid-to-creatinine ratio study.
Fraser AD; Worth D
Ther Drug Monit; 2002 Dec; 24(6):746-50. PubMed ID: 12451292
[TBL] [Abstract][Full Text] [Related]
7. Oxaprozin interference with urinary benzodiazepine immunoassays and noninterference with receptor assay.
Nishikawa T; Kamijo Y; Ohtani H; Fraser AD
J Anal Toxicol; 1999; 23(2):125-6. PubMed ID: 10192417
[No Abstract] [Full Text] [Related]
8. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and GC-MS cut-off values.
Fraser AD; Meatherall R
J Anal Toxicol; 1996; 20(4):217-23. PubMed ID: 8835658
[TBL] [Abstract][Full Text] [Related]
9. Limitations of EMIT benzodiazepine immunoassay for monitoring compliance of patients with benzodiazepine therapy even after hydrolyzing glucuronide metabolites in urine to increase cross-reactivity: comparison of immunoassay results with LC-MS/MS values.
Dixon RB; Floyd D; Dasgupta A
Ther Drug Monit; 2015 Feb; 37(1):137-9. PubMed ID: 25004136
[TBL] [Abstract][Full Text] [Related]
10. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
Darragh A; Snyder ML; Ptolemy AS; Melanson S
Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
[TBL] [Abstract][Full Text] [Related]
11. The online screening technique for urinary benzodiazepines: comparison with EMIT, FPIA, and GC-MS.
Beck O; Lin Z; Brodin K; Borg S; Hjemdahl P
J Anal Toxicol; 1997; 21(7):554-7. PubMed ID: 9399125
[TBL] [Abstract][Full Text] [Related]
12. Comparison of EMIT II, CEDIA, and DPC RIA assays for the detection of lysergic acid diethylamide in forensic urine samples.
Wiegand RF; Klette KL; Stout PR; Gehlhausen JM
J Anal Toxicol; 2002 Oct; 26(7):519-23. PubMed ID: 12423010
[TBL] [Abstract][Full Text] [Related]
13. Improved screening for benzodiazepine metabolites in urine using the Triage Panel for Drugs of Abuse.
Koch TR; Raglin RL; Kirk S; Bruni JF
J Anal Toxicol; 1994; 18(3):168-72. PubMed ID: 7914948
[TBL] [Abstract][Full Text] [Related]
14. Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC.
Fraser AD; Isner AF; Bryan W
J Anal Toxicol; 1993; 17(7):427-31. PubMed ID: 8309217
[TBL] [Abstract][Full Text] [Related]
15. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.
Pettersson Bergstrand M; Helander A; Hansson T; Beck O
Drug Test Anal; 2017 Apr; 9(4):640-645. PubMed ID: 27366870
[TBL] [Abstract][Full Text] [Related]
16. New fluorescence polarization immunoassays for analysis of barbiturates and benzodiazepines in serum and urine: performance characteristics.
Schwenzer KS; Pearlman R; Tsilimidos M; Salamone SJ; Cannon RC; Wong SH; Gock SB; Jentzen JJ
J Anal Toxicol; 2000; 24(8):726-32. PubMed ID: 11110029
[TBL] [Abstract][Full Text] [Related]
17. Improved CEDIA benzodiazepine assay eliminates sertraline crossreactivity.
Fitzgerald RL; Herold DA
J Anal Toxicol; 1997; 21(1):32-5. PubMed ID: 9013289
[TBL] [Abstract][Full Text] [Related]
18. CEDIA dau Benzodiazepine screening assay: a reformulation.
Meatherall RC; Fraser AD
J Anal Toxicol; 1998; 22(4):270-3. PubMed ID: 9681328
[TBL] [Abstract][Full Text] [Related]
19. Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS and LC-MS-MS.
Puzyrenko A; Wang D; Schneider R; Wallace G; Schreiber S; Brandt K; Gunsolus IL
J Anal Toxicol; 2022 Aug; 46(7):712-718. PubMed ID: 34557900
[TBL] [Abstract][Full Text] [Related]
20. Benzodiazepine screening using EMIT II and TDx: urine hydrolysis pretreatment required.
Meatherall R
J Anal Toxicol; 1994; 18(7):385-90. PubMed ID: 7861751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
